Somewhat Positive Press Coverage Somewhat Unlikely to Affect Henry Schein (HSIC) Stock Price

Media headlines about Henry Schein (NASDAQ:HSIC) have trended somewhat positive on Tuesday, according to Accern Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Henry Schein earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.9058234012245 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:

Henry Schein (NASDAQ HSIC) traded up $1.20 during mid-day trading on Tuesday, hitting $76.04. 2,080,000 shares of the company traded hands, compared to its average volume of 1,620,000. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.55 and a quick ratio of 0.86. Henry Schein has a fifty-two week low of $65.28 and a fifty-two week high of $93.50. The firm has a market capitalization of $11,930.00, a P/E ratio of 21.91, a PEG ratio of 1.91 and a beta of 0.99.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings data on Monday, November 6th. The company reported $0.87 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). The firm had revenue of $3.16 billion for the quarter, compared to analyst estimates of $3.05 billion. Henry Schein had a return on equity of 19.71% and a net margin of 4.52%. The company’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.84 earnings per share. equities research analysts anticipate that Henry Schein will post 3.6 earnings per share for the current fiscal year.

Henry Schein announced that its Board of Directors has initiated a share repurchase program on Monday, September 18th that permits the company to buyback $400.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 6.3% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s leadership believes its stock is undervalued.

Several equities analysts have commented on the stock. Evercore ISI assumed coverage on shares of Henry Schein in a report on Thursday, January 4th. They issued an “outperform” rating and a $81.00 price objective on the stock. Zacks Investment Research upgraded shares of Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, January 4th. Piper Jaffray Companies restated a “buy” rating and issued a $78.00 price target on shares of Henry Schein in a research note on Wednesday, December 27th. Deutsche Bank initiated coverage on shares of Henry Schein in a research note on Friday, December 8th. They issued a “buy” rating and a $79.00 price target on the stock. Finally, Morgan Stanley downgraded shares of Henry Schein from an “equal weight” rating to an “underweight” rating and set a $88.00 price target on the stock. in a research note on Wednesday, December 6th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and eight have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $84.23.

In other Henry Schein news, Director Barry J. Alperin sold 5,796 shares of the stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $70.76, for a total transaction of $410,124.96. Following the sale, the director now directly owns 48,172 shares in the company, valued at $3,408,650.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are accessing this news story on another website, it was stolen and republished in violation of U.S. & international copyright laws. The correct version of this news story can be read at

Henry Schein Company Profile

Henry Schein, Inc is a provider of healthcare products and services primarily to office-based dental, animal health and medical practitioners. The Company operates through two segments: healthcare distribution, and technology and value-added services. The healthcare distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products and vitamins.

Insider Buying and Selling by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with's FREE daily email newsletter.

Leave a Reply